Affimed (NASDAQ:AFMD) Given Consensus Rating of “Moderate Buy” by Brokerages

Affimed (NASDAQ:AFMD) has been given an average rating of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.00.

AFMD has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Affimed in a research report on Friday, November 15th. Stifel Nicolaus decreased their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday.

Hedge Funds Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Choreo LLC acquired a new position in shares of Affimed in the second quarter valued at about $54,000. Intellectus Partners LLC grew its stake in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Affimed in the third quarter valued at about $44,000. FMR LLC grew its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Affimed Price Performance

NASDAQ AFMD opened at $2.64 on Friday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average price is $3.43 and its two-hundred day moving average price is $4.47. Affimed has a 1 year low of $2.64 and a 1 year high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. Equities research analysts expect that Affimed will post -3.91 earnings per share for the current year.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.